Literature DB >> 23208492

In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.

B Casar1, I Rimann1, H Kato2, S J Shattil3, J P Quigley1, E I Deryugina1.   

Abstract

Specific cleavage of the transmembrane molecule, CUB domain-containing protein-1 (CDCP1), by plasmin-like serine proteases induces outside-in signal transduction that facilitates early stages of spontaneous metastasis leading to tumor cell intravasation, namely cell escape from the primary tumor, stromal invasion and transendothelial migration. We identified active β1 integrin as a biochemical and functional partner of the membrane-retained 70-kDa CDCP1 fragment, newly generated from its full-length 135-kDa precursor though proteolytic cleavage by serine proteases. Both in cell cultures and in live animals, active β1 integrin complexed preferentially with functionally activated, phosphorylated 70-kDa CDCP1. Complexing of β1 integrin the 70-kDa with CDCP1 fragment induced intracellular phosphorylation signaling, involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation. Thus, inhibition of FAK/PI3K activities by specific inhibitors as well as short-hairpin RNA downregulation of β1 integrin significantly reduced FAK/Akt phosphorylation under conditions where CDCP1 was processed by serine proteases, indicating that FAK/PI3K/Akt pathway operates downstream of cleaved CDCP1 complexed with β1 integrin. Furthermore, this complex-dependent signaling correlated positively with high levels of tumor cell intravasation and dissemination. Correspondingly, abrogation in vivo of CDCP1 cleavage either by unique cleavage-blocking monoclonal antibody 10-D7 or by inhibition of proteolytic activity of plasmin-like serine proteases with aprotinin prevented β1 integrin/CDCP1 complexing and downstream FAK/Akt signaling concomitant with significant reduction of stromal invasion and spontaneous metastasis. Therefore, β1 integrin appears to serve as a motility-regulating partner mediating cross-talk between proteolytically cleaved, membrane-retained CDCP1 and members of FAK/PI3K/Akt pathway. This CDCP1 cleavage-induced signaling cascade constitutes a unique mechanism, independent of extracellular matrix remodeling, whereby a proteolytically cleaved CDCP1 regulates in vivo locomotion and metastasis of tumor cells through β1 integrin partnering. Our findings indicate that CDCP1 cleavage, occurring at the apex of a β1 integrin/FAK/PI3K/Akt signaling cascade, may represent a therapeutic target for CDCP1-positive cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208492      PMCID: PMC3931462          DOI: 10.1038/onc.2012.547

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

1.  The C2 domain of PKCdelta is a phosphotyrosine binding domain.

Authors:  Cyril H Benes; Ning Wu; Andrew E H Elia; Tejal Dharia; Lewis C Cantley; Stephen P Soltoff
Journal:  Cell       Date:  2005-04-22       Impact factor: 41.582

2.  Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination.

Authors:  Elena I Deryugina; Andries Zijlstra; Juneth J Partridge; Tatyana A Kupriyanova; Mark A Madsen; Thales Papagiannakopoulos; James P Quigley
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

3.  Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain.

Authors:  A Luque; M Gómez; W Puzon; Y Takada; F Sánchez-Madrid; C Cabañas
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

4.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

5.  Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer.

Authors:  M Scherl-Mostageer; W Sommergruber; R Abseher; R Hauptmann; P Ambros; N Schweifer
Journal:  Oncogene       Date:  2001-07-19       Impact factor: 9.867

6.  Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells.

Authors:  Sara E Perry; Philip Robinson; Alan Melcher; Philip Quirke; Hans-Jörg Bühring; Graham P Cook; G Eric Blair
Journal:  FEBS Lett       Date:  2007-02-20       Impact factor: 4.124

7.  Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia.

Authors:  Tod A Brown; Tai Mei Yang; Tatiana Zaitsevskaia; Yuping Xia; Clarence A Dunn; Randy O Sigle; Beatrice Knudsen; William G Carter
Journal:  J Biol Chem       Date:  2004-01-22       Impact factor: 5.157

8.  CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.

Authors:  Takamasa Uekita; Lin Jia; Mako Narisawa-Saito; Jun Yokota; Tohru Kiyono; Ryuichi Sakai
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

9.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

Review 10.  Cell surface remodeling by plasmin: a new function for an old enzyme.

Authors:  Elena I Deryugina; James P Quigley
Journal:  J Biomed Biotechnol       Date:  2012-10-14
View more
  49 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation.

Authors:  Heather J Wright; Jue Hou; Binzhi Xu; Marvin Cortez; Eric O Potma; Bruce J Tromberg; Olga V Razorenova
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-24       Impact factor: 11.205

3.  Targeting CDCP1 dimerization in triple-negative breast cancer.

Authors:  Heather J Wright; Alice M Police; Olga V Razorenova
Journal:  Cell Cycle       Date:  2016-06-30       Impact factor: 4.534

4.  Regulation of inside-out β1-integrin activation by CDCP1.

Authors:  Sara G Pollan; Fangjin Huang; Jamie M Sperger; Joshua M Lang; Colm Morrissey; Anne E Cress; C Y Chu; Neil A Bhowmick; Sungyong You; Michael R Freeman; Danislav S Spassov; Mark M Moasser; William G Carter; Shakti Ranjan Satapathy; Kavita Shah; Beatrice S Knudsen
Journal:  Oncogene       Date:  2018-03-07       Impact factor: 9.867

5.  Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

Authors:  Y He; A C Wu; B S Harrington; C M Davies; S J Wallace; M N Adams; J S Palmer; D K Roche; B G Hollier; T F Westbrook; H Hamidi; G E Konecny; B Winterhoff; N P Chetty; A J Crandon; N B Oliveira; C M Shannon; A V Tinker; C B Gilks; J I Coward; J W Lumley; L C Perrin; J E Armes; J D Hooper
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

6.  Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.

Authors:  Anna Moroz; Yung-Hua Wang; Jeremy M Sharib; Junnian Wei; Ning Zhao; Yangjie Huang; Zhuo Chen; Alexander J Martinko; Jie Zhuo; Shion A Lim; Lydia H Zhang; Youngho Seo; Sean Carlin; Kevin K Leung; Eric A Collisson; Kimberly S Kirkwood; James A Wells; Michael J Evans
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

Review 7.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

8.  FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.

Authors:  Yan-Hong Cui; Hyeonmi Kim; Minyoung Lee; Joo Mi Yi; Rae-Kwon Kim; Nizam Uddin; Ki-Chun Yoo; Jae Hyeok Kang; Mi-Young Choi; Hyuk-Jin Cha; Ok-Seon Kwon; In-Hwa Bae; Min-Jung Kim; Neha Kaushik; Su-Jae Lee
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

9.  Common mechanism of pathogenesis in various types of metastatic osteosarcoma.

Authors:  Dongqi Wang; Zongrang Song; Zhan Wang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

10.  Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer.

Authors:  Katarzyna Starska; Ewa Forma; Paweł Jóźwiak; Iwona Lewy-Trenda; Marian Danilewicz; Olga Stasikowska-Kanicka; Michał Skóra; Katarzyna Kolary; Jakub Miazga; Anna Krześlak; Magdalena Bryś
Journal:  Tumour Biol       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.